


# New Landmark Report Unveils a Decade of AI Transformation in Drug Discovery

*Features historical drug pipeline analysis of leading AI platforms in drug discovery*

LONDON, ENGLAND, UNITED KINGDOM, April 3, 2024

/EINPresswire.com/ -- In a first-of-its kind analysis, BiopharmaTrend is excited to announce the release of its seminal report, "[It's Been a Decade of AI in the Drug Discovery Race. What's Next?](#)," marking the first exploration of the artificial intelligence (AI) advent in the pharmaceutical industry, including historical drug pipeline analysis of leading AI platform companies.



The report also includes an overview of merger and acquisition (M&A) deals in the AI drug discovery sector between 2018-2024, and a brief financial analysis of several leading players to benchmark their performance on different metrics.

“

The report highlights a historical drug candidate pipeline analysis of 10 leading AI platforms in drug discovery.”

*Dr. Andrii Buvailo*

The report is based on the data about more than 500 AI companies in the BiopharmaTrend subscription-based analytical tool "[The State of AI in the Biopharma Industry](#)," as well as extensive industry research.

The report highlights a historical drug candidate pipeline analysis of 10 leading AI platforms in drug discovery.

The report and its analytical backend infrastructure can

serve as a platform for “apples to apples” benchmarking of AI in drug discovery companies, and conducting technology scouting and competitor intelligence research in this space.

This historical analysis features a year-by-year pipeline progression chart for the last 5 years,

including information about drug candidate progression from early drug discovery to the clinical stage, and offers a unique perspective on the developmental progress and clinical achievements of the companies, illustrating the development dynamics.

Furthermore, the report includes an overview of key mergers and acquisitions (M&As) within the AI for drug discovery sector since 2018, highlighting more than 30 significant deals mapped year by year. This overview not only illustrates the sector's dynamic consolidation but also emphasizes the strategic shifts and alignments shaping the future of AI-driven drug discovery and development.

However, despite the initial surge of enthusiasm, the journey has been marked by both breakthroughs and setbacks.

The report candidly addresses the challenges faced, including clinical trial setbacks and the reevaluation of business models, adjusting strategies in response to the shifting landscape.

Noteworthy, R&D partnerships in the AI for drug discovery space are shifting from pilot projects towards more strategic partnerships, with big pharma increasingly leveraging AI internally rather than relying on external collaborations, and focusing on partnering with leading platforms rather than emerging AI startups. The entry barrier for new AI in drug discovery companies is increasing.

Looking ahead, the report anticipates the continued influence of big tech companies like NVIDIA, Alphabet, and Microsoft, which are set to play pivotal roles in shaping the sector's future.

The report underscores the critical importance of unique biological data and the integration of AI with high-throughput experimental capabilities, as demonstrated by companies like Insilico Medicine, Recursion Pharmaceuticals, and XtalPi.

"This report is an essential read for anyone involved in the biopharma industry," said Dr. Andrii Buvailo, co-founder and editor at BiopharmaTrend. "Not only does it map out in broad strokes the journey of AI in drug discovery over the past decade or so, but it also provides a lens through which we can view future innovations and collaborations that will shape the next era of medicine."

#### About BiopharmaTrend

BiopharmaTrend (BPT Analytics Ltd.) is a leading provider of industry insights and competitive intelligence related to the advent of emerging technologies, such as artificial intelligence, in the pharmaceutical and biotech industries.

Visit [www.biopharmatrend.com](http://www.biopharmatrend.com) for more information.

Andrii Buvailo  
BiopharmaTrend  
editor@biopharmatrend.com

---

This press release can be viewed online at: <https://www.einpresswire.com/article/700668181>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.